Recent participation (within 28 days) in other research studies 
Recent significant blood donation or plasma donation 
Pregnant or lactating 
Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) 
Recent (2-year) history or evidence of alcoholism or drug abuse 
History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease 
Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study 
Drug allergies to quinine sulfate or rosiglitazone       
    

NCT00785213_exc_T1
Temporal
within 28 days
NCT00785213_exc_T4
Procedure
blood donation
NCT00785213_exc_T5
Procedure
plasma donation
NCT00785213_exc_T6
Qualifier
significant
NCT00785213_exc_T8
Temporal
Recent
NCT00785213_exc_T9
Scope
blood donation or plasma donation
NCT00785213_exc_T7
Condition
Pregnant
NCT00785213_exc_T11
Condition
lactating
NCT00785213_exc_T13
Value
positive
NCT00785213_exc_T14
Temporal
at screening
NCT00785213_exc_T15
Measurement
human immunodeficiency virus (HIV)
NCT00785213_exc_T16
Measurement
hepatitis C virus (HCV)
NCT00785213_exc_T17
Measurement
hepatitis B surface antigen (HbsAg)
NCT00785213_exc_T12
Scope
human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)
NCT00785213_exc_T18
Condition
alcoholism
NCT00785213_exc_T19
Condition
drug abuse
NCT00785213_exc_T20
Observation
history
NCT00785213_exc_T21
Mood
evidence
NCT00785213_exc_T22
Temporal
Recent
NCT00785213_exc_T23
Temporal
2-year
NCT00785213_exc_T24
Scope
alcoholism or drug abuse
NCT00785213_exc_T25
Scope
history or evidence
NCT00785213_exc_T27
Drug
drugs known to inhibit cytochrome (CYP) P450 enzymes
NCT00785213_exc_T28
Drug
drugs known to induce cytochrome (CYP) P450 enzymes
NCT00785213_exc_T29
Drug
drugs known to inhibit P-glycoprotein (P-gp)
NCT00785213_exc_T30
Drug
drugs known to induce P-glycoprotein (P-gp)
NCT00785213_exc_T31
Temporal
within 28 days prior to the first dose
NCT00785213_exc_T32
Temporal
throughout the study
NCT00785213_exc_T33
Scope
drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp)
NCT00785213_exc_T34
Condition
allergies
NCT00785213_exc_T36
Drug
quinine sulfate
NCT00785213_exc_T37
Drug
rosiglitazone
NCT00785213_exc_T35
Scope
quinine sulfate or rosiglitazone